OCU400 shows significant long-term improvements in visual function and mobility for retinitis pigmentosa patients, with a strong safety profile. Ocugen, Inc. announced positive results from its Phase ...
Immunocore reports positive initial data for HIV treatment candidate IMC-M113V, showing safety and signs of viral control post-treatment. The observation of delayed viral rebound and/or viremia ...
ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results